All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q1 report for BIOGEN, INC. on April 20, 2026, reporting $60,000 in lobbying income.

Lobbying for BIOGEN, INC. · Biotechnology company.

All filings by DLA PIPER LLP (US) · Everything BIOGEN, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Taxation/Internal Revenue Code

Issues related to tax reform.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property.

Health Issues

Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.

Medical/Disease Research/Clinical Labs

Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.

Pharmacy

Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.